Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X about a paper by Jack Cuzick and Peter Sasieni published in the British Journal of Cancer:
“Interpreting the results of noninferiority trials – a review: British Journal of Cancer
- great review
- option of defining advantage beyond efficacy
- The key is to define the clinical noninferiority margin
- Determining its efficacy versus no treatment can be a challenge.”
Title: Interpreting the results of noninferiority trials – a review
Authors: Jack Cuzick, Peter Sasieni
You can read the Full Article in the British Journal of Cancer.
More posts featuring Arndt Vogel.
